Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Spyre Therapeutics Inc. (SYRE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: SYRE (1-star) is a SELL. SELL since 3 days. Profits (-10.78%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $54.89
1 Year Target Price $54.89
| 10 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -50.3% | Avg. Invested days 22 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.02B USD | Price to earnings Ratio - | 1Y Target Price 54.89 |
Price to earnings Ratio - | 1Y Target Price 54.89 | ||
Volume (30-day avg) 11 | Beta 2.83 | 52 Weeks Range 10.91 - 40.26 | Updated Date 08/15/2025 |
52 Weeks Range 10.91 - 40.26 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.53 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-08-05 | When - | Estimate -0.7538 | Actual -0.49 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -28.48% | Return on Equity (TTM) -49.83% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 864010185 | Price to Sales(TTM) 650.22 |
Enterprise Value 864010185 | Price to Sales(TTM) 650.22 | ||
Enterprise Value to Revenue 1964.91 | Enterprise Value to EBITDA -7.96 | Shares Outstanding 60401000 | Shares Floating 46670614 |
Shares Outstanding 60401000 | Shares Floating 46670614 | ||
Percent Insiders 8.71 | Percent Institutions 108.37 |
Upturn AI SWOT
Spyre Therapeutics Inc.
Company Overview
History and Background
Spyre Therapeutics, Inc. is a biotechnology company focused on developing antibody therapeutics for inflammatory bowel disease (IBD). It was founded in 2022. The company is relatively new and rapidly evolving, having recently executed some key acquisitions.
Core Business Areas
- Gastroenterology: Develops novel therapies to target inflammatory bowel diseases (IBD). Focus is on antibodies with improved efficacy, safety, and convenience for patients with Crohn's disease and ulcerative colitis.
Leadership and Structure
The leadership team consists of experienced professionals in the biotechnology and pharmaceutical industries. Specific organizational structure details beyond the leadership team are not widely available in public sources.
Top Products and Market Share
Key Offerings
- SPY001: An anti-TL1A antibody designed to improve efficacy and administration convenience compared to existing anti-TL1A therapies. Currently in development. Competitors include Prometheus Biosciences (acquired by Merck) and others developing TL1A inhibitors.
- SPY002: An anti-alpha 4 beta 7 antibody with the goal to achieve best-in-class efficacy and reduced immunogenicity through improved design. Currently in development. Competitors include Takeda's Entyvio.
Market Dynamics
Industry Overview
The IBD market is large and growing, driven by increasing prevalence of Crohn's disease and ulcerative colitis. There is a high unmet need for more effective and safer therapies, particularly those with improved convenience.
Positioning
Spyre Therapeutics aims to develop best-in-class antibody therapeutics that address the limitations of existing IBD treatments, such as incomplete efficacy, inconvenient administration, and safety concerns. They are positioned as an innovative company looking to disrupt the market with improved antibody engineering.
Total Addressable Market (TAM)
The global IBD market is projected to reach $26.7 billion by 2028. Spyre aims to capture a significant portion of this TAM by offering superior therapies, though it's too early to define a market share target due to its early clinical stage.
Upturn SWOT Analysis
Strengths
- Novel antibody engineering platform
- Experienced leadership team
- Focus on a large and growing market with unmet needs
- Potential for best-in-class therapies
Weaknesses
- Early stage of development
- Limited clinical data
- Dependence on successful clinical trials
- Relatively new company
Opportunities
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Expansion into other autoimmune diseases
- Acquisition by a larger pharmaceutical company
Threats
- Clinical trial failures
- Competition from established players
- Regulatory hurdles
- Patent challenges
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- MRK
- TAK
Competitive Landscape
Spyre competes with established pharmaceutical companies with marketed IBD products and other biotechnology companies developing novel therapies. Their competitive advantage lies in the potential for improved efficacy, safety, and convenience of their antibody therapeutics. The primary disadvantage is being a development stage company with no approved products.
Growth Trajectory and Initiatives
Historical Growth: Not applicable due to the company's recent formation. Historical growth is focused on rapid preclinical and early clinical development.
Future Projections: Future growth is dependent on successful clinical trials and regulatory approvals. Analyst estimates vary widely depending on perceived clinical success. It's too premature to give numerical projections.
Recent Initiatives: Focus on advancing SPY001 and SPY002 through clinical development, business development and partnering.
Summary
Spyre Therapeutics is a young biotechnology company focused on developing improved antibody therapies for IBD. Their approach centers around novel engineering to achieve best-in-class efficacy and safety. As a development-stage company, Spyre carries significant risk but also considerable potential upside with clinical trial success. They need to continue demonstrating clinical promise and maintain sufficient capital.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Spyre Therapeutics Investor Relations
- SEC Filings
- Third-party market research reports on the IBD market
- Analyst reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. The biotechnology industry is inherently risky, and investors should conduct their own due diligence before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Spyre Therapeutics Inc.
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2016-04-07 | CEO & Director Dr. Cameron Turtle DPHIL, Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 87 | Website https://www.spyre.com |
Full time employees 87 | Website https://www.spyre.com | ||
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.